FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631

Infants with KMT2A ‐rearranged acute lymphoblastic leukemia ( KMT2A -r ALL) have a poor prognosis. KMT2A -r ALL overexpresses FLT3, and the FLT3 inhibitor (FLT3i) lestaurtinib potentiates chemotherapy‐induced cytotoxicity in preclinical models. Children’s Oncology Group (COG) AALL0631 tested whether...

Full description

Saved in:

Bibliographic Details
Published in:	Leukemia Vol. 35; no. 5; pp. 1279 - 1290
Main Authors:	Brown, Patrick A., Kairalla, John A., Hilden, Joanne M., Dreyer, ZoAnn E., Carroll, Andrew J., Heerema, Nyla A., Wang, Cindy, Devidas, Meenakshi, Gore, Lia, Salzer, Wanda L., Winick, Naomi J., Carroll, William L., Raetz, Elizabeth A., Borowitz, Michael J., Small, Donald, Loh, Mignon L., Hunger, Stephen P.
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01.05.2021 Nature Publishing Group
Subjects:	631/67/1059/602 631/67/1990/283/2125 82 96/95 Acute lymphoblastic leukemia Acute lymphocytic leukemia Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Cancer in children Cancer Research Carbazoles - therapeutic use Chemotherapy Children Critical Care Medicine Cytotoxicity Drug therapy Female fms-Like Tyrosine Kinase 3 - antagonists & inhibitors Furans Genetic aspects Hematology Histone-Lysine N-Methyltransferase - metabolism Humans Infant Infants Inhibitors Intensive Internal Medicine Leukemia Lymphatic leukemia Male Medical prognosis Medicine Medicine & Public Health Methods Myeloid-Lymphoid Leukemia Protein - metabolism Oncology Pediatric research Pharmacodynamics Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Protein Kinase Inhibitors - therapeutic use Toxicity United States
ISSN:	0887-6924, 1476-5551, 1476-5551
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!